

July 2, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir / Madam,

Sub: Intimation of merger of Pharmacin B.V., with Agile Pharma B.V., wholly owned stepdown subsidiaries of the Company.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is to inform that Pharmacin B.V., a wholly owned stepdown subsidiary merged with its holding company, Agile Pharma B.V., also a wholly owned stepdown subsidiary of the Company with effect from July 1, 2025. Both the companies are incorporated in The Netherlands.

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a disclosure in an **Annexure** to this letter.

Please take the information on record.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl: Annexure

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500 038, Telangana, INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure

S. No.	Particulars	Details						
a	name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.;	<p>Pharmacin B.V, a wholly owned step-down subsidiary (“Pharmacin”) merged with its holding company, Agile Pharma B.V., another step-down subsidiary of the Company (“Agile”) with effect from July 1, 2025. Both Pharmacin and Agile are incorporated in The Netherlands.</p> <p>Following are the turnover details of the companies for the year ended March 31, 2025:</p> <table><tr><th>Name of the Company</th><th>Turnover Rs. in Million</th></tr><tr><td>Agile Pharma B.V</td><td>66.4</td></tr><tr><td>Pharmacin B.V</td><td>197.9</td></tr></table>	Name of the Company	Turnover Rs. in Million	Agile Pharma B.V	66.4	Pharmacin B.V	197.9
Name of the Company	Turnover Rs. in Million							
Agile Pharma B.V	66.4							
Pharmacin B.V	197.9							
b	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	<p>Both Agile and Pharmacin being wholly owned step-down subsidiaries of the Company, they are related parties as per Regulation 2 (zb) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</p> <p>The transaction is undertaken between the wholly owned step-down subsidiaries of the Company and accordingly there is no impact on a consolidated basis.</p> <p>As per the provisions of Section 188 of Companies Act, 2013 and Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provisions relating to related party transactions are not applicable in respect of transactions between wholly owned subsidiaries of a holding company.</p>						
c	area of business of the entity(ies);	Manufacturing and marketing of pharmaceutical products.						
d	rationale for amalgamation/ merger;	Pharmacin is a wholly owned subsidiary of Agile. This merger will enhance the substantive character of Agile with business activity and employees of its own and also saving regulatory and compliance expenses.						
e	in case of cash consideration – amount or otherwise share exchange ratio;	Nil						
f	brief details of change in shareholding pattern (if any) of listed entity.	No change in the shareholding pattern of the Company.						

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038, Telangana, INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com